(Q35160324)

6 August 2017

1 reference

title

Translation of immunological knowledge into better treatments of chronic hepatitis B. (English)

1 reference

6 August 2017

1 reference

1 reference

Antonio Bertoletti

1

0 references

author name string

Nikolai V Naoumov

series ordinal

2

1 reference

6 August 2017

publication date

1 July 2003

1 reference

6 August 2017

published in

Journal of Hepatology

1 reference

6 August 2017

volume

39

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

115-124

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

6 August 2017

1 reference

7 January 2021

Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Therapeutic dendritic-cell vaccine for simian AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Long-lasting memory T cell responses following self-limited acute hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or After HBs vaccination: Stimulation of thein vitroantibody response by interferon gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Deficiencies in the acute-phase cell-mediated immune response to viral antigens are associated with development of chronic woodchuck hepatitis virus infection following neonatal inoculation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Detection of a new antibody system reacting with Dane particles in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Hepatitis B Immune Globulin for Accidental Exposures among Medical Personnel: Final Report of a Multicenter Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Viral escape and the failure of cellular immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Impairment of CD4(+) T cell responses during chronic virus infection prevents neutralizing antibody responses against virus escape mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Initial and innate responses to viral infections--pattern setting in immunity or disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Prospective study of cellular immunity to hepatitis-B-virus antigens from the early incubation phase of acute hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Hepatitis B antigens in serum and liver of chimpanzees acutely infected with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Pathogenesis of experimental neonatal woodchuck hepatitis virus infection: chronicity as an outcome of infection is associated with a diminished acute hepatitis that is temporally deficient for the expression of interferon gamma and tumor necrosis f

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Temporal pathogenesis of experimental neonatal woodchuck hepatitis virus infection: increased initial viral load and decreased severity of acute hepatitis during the development of chronic viral infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Natural killer T cell activation inhibits hepatitis B virus replication in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Cutting edge: Inhibition of hepatitis B virus replication by activated NK T cells does not require inflammatory cell recruitment to the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Hepatic interferon-alpha gene transcripts and products in liver specimens from acute and chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: detection by suppression-subtractive hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Identification of the hepatitis B virus factor that inhibits expression of the beta interferon gene

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Functional analysis of HBV genomes from patients with fulminant hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Towards a rational therapy for hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Clearance of hepatitis B surface antigen after bone marrow transplantation: Role of adoptive immunity transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Efficacy and limitations of a specific immunotherapy in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Characterization of the T cell recognition of hepatitis B surface antigen (HBsAg) by good and poor responders to hepatitis B vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

The hepatitis B virus e antigen cannot pass the murine placenta efficiently and does not induce CTL immune tolerance in H-2b mice in utero

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Molecular features of the hepatitis B virus nucleocapsid T-cell epitope 18-27: interaction with HLA and T-cell receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Assessing CD8 T cell number and dysfunction in the presence of antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

The serology of chronic hepatitis B infection revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B - restoration by exogenous interleukin-12.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Hepatitis B virus surface antigen suppresses the activation of monocytes through interaction with a serum protein and a monocyte-specific receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Genetic variation in hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Genetic variability in hepatitis B viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Cytotoxic T cells and viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Noncytolytic control of viral infections by the innate and adaptive immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Noncytopathic clearance of lymphocytic choriomeningitis virus from the hepatocyte.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Contribution of virus-specific CD8+ cytotoxic T cells to virus clearance or pathologic manifestations of influenza virus infection in a T cell receptor transgenic mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Hepatitis B associated liver failure following bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Hepatitis B virus immunopathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Cellular and humoral immune response to hepatitis B virus structural proteins in mice after DNA-based immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Relationship between expression of hepatitis B virus antigens in isolated hepatocytes and autologous lymphocyte cytotoxicity in patients with chronic hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Protection against hepatitis B virus infection by immunization with hepatitis B core antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Immunization with recombinant woodchuck hepatitis virus nucleocapsid antigen or hepatitis B virus nucleocapsid antigen protects woodchucks from woodchuck hepatitis virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Alternative processing of endogenous or exogenous antigens extends the immunogenic, H-2 class I-restricted peptide repertoire

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900126-0

7 January 2021

10.1016/S0168-8278(03)00126-0

Identifiers

DOI

1 reference

6 August 2017

1 reference